|1.||Christiansen, C: 2 articles (03/2003 - 02/2001)|
|2.||Stakkestad, J A: 2 articles (03/2003 - 02/2001)|
|3.||Delmas, P D: 2 articles (03/2003 - 02/2001)|
|4.||Riis, B J: 2 articles (03/2003 - 02/2001)|
|5.||Shelly, Wendy: 1 article (03/2008)|
|6.||Krishnan, Venkatesh: 1 article (03/2008)|
|7.||Jaffe, Robert B: 1 article (03/2008)|
|8.||Draper, Michael W: 1 article (03/2008)|
|9.||Wong, Mayme: 1 article (03/2008)|
|10.||Elshafie, Mona: 1 article (02/2008)|
03/28/2003 - "Levormeloxifene prevents the postmenopausal bone loss, but the lowest effective dose is unknown."
02/01/2001 - "Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy."
09/01/2002 - "Levormeloxifene is a selective estrogen receptor modulator that was developed for the purpose of the treatment and prevention of postmenopausal osteoporosis. "
01/01/2006 - "Levormeloxifene is a selective estrogen receptor modulator that was developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. "
10/01/1997 - "The present study was undertaken to investigate the effect of the L-enantiomer (levormeloxifene) and the d-enantiomer (d-ormeloxifene) on the development of atherosclerosis. "
10/01/1997 - "Like estrogen, levormeloxifene did not inhibit atherosclerosis in the endothelium-denuded site of aorta. "
10/01/1997 - "In the long-term experiment, levormeloxifene, in contrast to d-ormeloxifene, significantly reduced atherosclerosis by 50% in the undamaged arterial wall of both female and male rabbits. "
08/15/1997 - "The results for levormeloxifene suggest a common mechanism of action for estrogen and partial estrogen receptor agonists on atherogenesis."
|3.||Uterine Prolapse (Vaginal Prolapse)
03/28/2003 - "In the levormeloxifene groups, a total of eight women had utero-vaginal prolapse and five women reported urinary incontinence (including worsening of a previously existing condition). "
09/01/2005 - "Levormeloxifene and idoxifene, on the contrary, were noted to increase uterine prolapse and incontinence during phase III trials that prematurely terminated. "
|4.||Pelvic Organ Prolapse
09/01/2002 - "This was a multicentered prospective study of healthy women aged >or=65 years with osteoporosis who were randomized to blindly receive placebo or levormeloxifene 0.5 mg or 1.25 mg daily as part of a planned 3-year osteoporosis treatment study. "
09/01/2002 - "Levormeloxifene results in multiple adverse gynecologic and other events in postmenopausal women with osteoporosis."
09/01/2002 - "Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study."
|2.||Selective Estrogen Receptor Modulators (SERM)
|8.||LY 353381 (LY353381)
|9.||tartrate salt cis- 1R- (4'- pyrrolidinoethoxyphenyl)- 2S- phenyl- 6- hydroxy- 1,2,3,4- tetrahydronaphthalene (Lasofoxifene)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|2.||Estrogen Replacement Therapy